2023
Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial
Fanucci K, Bai Y, Pelekanou V, Nahleh Z, Shafi S, Burela S, Barlow W, Sharma P, Thompson A, Godwin A, Rimm D, Hortobagyi G, Liu Y, Wang L, Wei W, Pusztai L, Blenman K. Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial. Npj Breast Cancer 2023, 9: 38. PMID: 37179362, PMCID: PMC10182981, DOI: 10.1038/s41523-023-00535-0.Peer-Reviewed Original ResearchPathologic complete responseBreast cancerComplete responseTIL scoreBreast Cancer Pathologic Complete ResponseTumor-infiltrating lymphocyte scoresEvent-free survivalNeoadjuvant chemotherapy trialsLymphocyte measurementsLymphocyte scoreNeoadjuvant chemotherapyChemotherapy trialsMean pretreatmentResidual diseaseTIL quantificationPredictive valuePretreatment samplesResponse discriminationScoresStrong positive correlationPositive correlation
2020
Validation of an immunomodulatory gene signature algorithm to predict response to neoadjuvant immunochemotherapy in patients with primary triple-negative breast cancer.
Iwase T, Pusztai L, Blenman K, Li X, Seitz R, Nielsen T, Schweitzer B, Hout D, Bailey D, Zhang X, Shen Y, Ueno N. Validation of an immunomodulatory gene signature algorithm to predict response to neoadjuvant immunochemotherapy in patients with primary triple-negative breast cancer. Journal Of Clinical Oncology 2020, 38: 3117-3117. DOI: 10.1200/jco.2020.38.15_suppl.3117.Peer-Reviewed Original ResearchPrimary triple-negative breast cancerTriple-negative breast cancerPathological complete responsePD-L1 IHCIM subtypesPredictive valueNeoadjuvant immunochemotherapyBreast cancerPhase I/II trialPretreatment core-needle biopsiesAntigen-presenting immune cellsPossible predictive markerImmune cell populationsImmune cell processesCore needle biopsyNegative predictive valuePositive predictive valueStrong predictive valuePositive likelihood ratioNegative likelihood ratioImmunomodulatory subtypeNeoadjuvant immunotherapyII trialLikelihood ratioComplete response